Ingredient news
Sunflower PS Trial in Healthy Children Finds Mixed Results
By Nutranexa News |
A 2025 randomized trial of sunflower phosphatidylserine in healthy children found no significant overall differences on primary or secondary outcomes, while suggesting lower-performing subgroups may warrant further study.
What Was Studied
The Nutritional Journal paper evaluated sunflower phosphatidylserine supplementation in healthy children aged 8 to 12 years using a randomized controlled design.
That makes it relevant for buyers watching whether PS evidence is moving beyond older-adult cognition and into younger age-group product concepts.
What Researchers Found
According to the PubMed summary, the trial found no differences in the primary and secondary outcomes overall.
The same summary says the authors believe future work should focus on children with below-median performance, who may be more likely to benefit from supplementation.
Buyer Takeaway
For ingredient buyers, this is a reminder that pediatric or family-positioned concepts need sharper population targeting than broad 'healthy children' messaging might imply.
Null or mixed results can still be commercially useful because they narrow where follow-up formulation and substantiation work should be focused.